Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRASG12D inhibition reprograms the tumor-induced immunosuppressive environment and enhances NK cell-mediated antitumor immunity.

Science advances - 24 Jul 2026

Hu Tuo, Mo Taiwei, Wang Lin, Ke Qiuqing, Chi Liangjie, Chen Hongyuan, Xu Chao, Huang Chenshen, Lin Aiping, Cai Shaoxin, Chen Haiyu, Wang Wenyu, Jin Longyang, Zhao Junzhang, Liu Haoyun, Liu Chuanyuan, Baihetiyaer Yimamu, Tuersun Abudumaimaitijiang, Abulimiti Abuduhalike, Zheng Yan, Wang Zuwei, Chen Shi, Cao Jie, Lu Shiyun, Huang Xueping, Xue Fangqin, He Chunbo

Abstract excerpt

KRASG12D mutation drives oncogenic progression and creates an immunosuppressive microenvironment in cancers like pancreatic ductal adenocarcinoma and colorectal cancer. We investigate the immunomodulatory mechanisms of the KRASG12D inhibition and its synergy with natural killer (NK) cell therapies. We demonstrate that KRASG12D inhibition with MRTX1133 remodels the immune landscape by reducing myeloid-derived...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to IFNGR1 gene

Share to Killer Cells, Natural

Share to Mutation

Share to Myeloid-Derived Suppressor Cells

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 42490421
DOI: 10.1126/sciadv.aec9236
PMCID: PMC13394479

Genes

IFNGR1
ICAM1
ULBP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRASG12D inhibition reprograms the tumor-induced immunosuppressive environment and enhances NK cell-mediated antitumor immunity.PMID 42490421Read ↗

Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancerSemantic proximity Read ↗

KRAS G12C inhibition and innate immune targeting.Semantic proximity Read ↗

Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and DegradationSemantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.Semantic proximity Read ↗

Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencySemantic proximity Read ↗

A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunitySemantic proximity Read ↗

Tumor Cell‐Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic TumorigenesisSemantic proximity Read ↗

Fatty Acids Support the Fitness and Functionality of Tumor-Resident CD8+ T Cells by Maintaining SCML4 ExpressionSemantic proximity Read ↗

MLLT6 maintains PD‐L1 expression and mediates tumor immune resistanceSemantic proximity Read ↗

Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor MicroenvironmentSemantic proximity Read ↗

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.